Feraheme® (ferumoxytol)

Feraheme is covered for adults (≥18) for FDA‑approved iron deficiency anemia indications — intolerance or unsatisfactory response to oral iron and chronic kidney disease — and for the compendial off‑label indication of iron deficiency in heart failure; pediatric use and other unlisted indications are excluded. Coverage requires documentation of age and diagnosis, specialist prescription/consult when specified (nephrologist or hematologist for CKD; cardiologist or hematologist for heart failure), and for non‑CKD anemia evidence of failed/intolerant oral iron or malabsorption or concurrent ESA therapy or cancer/chemotherapy‑related anemia, with approvals limited to 12 months and recommended dosing of 510 mg IV followed by 510 mg IV 3–8 days later.

"Iron deficiency in patients with heart failure (Approved Off-label Compendial Use)."

Sign up to see full coverage criteria, indications, and limitations.